Cost-effectiveness analysis of outpatient bispecific antibody treatment for multiple myeloma.
Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.
This study tests if treating patients with relapsed or refractory multiple myeloma using bispecific antibodies in an outpatient setting is more effective and cost-friendly than traditional hospital care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Toulouse Academic / other |
| Drugs / interventions | teclistamab, elranatamab, talquetamab, immunotherapy |
| Locations | 1 site (Toulouse) |
| Trial ID | NCT06846905 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the cost-utility of escalating doses of bispecific antibodies in patients with relapsed or refractory multiple myeloma. It compares the outcomes of patients treated in an outpatient setting versus those in a conventional hospital unit, focusing on quality of life and clinical data collected at multiple time points. The study utilizes validated questionnaires to assess patient utility and quality of life, while also gathering economic data related to hospital stays. The aim is to determine the feasibility and effectiveness of outpatient treatment for this patient population.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with relapsed or refractory multiple myeloma who are receiving specific bispecific antibody treatments.
Not a fit: Patients who are illiterate or have language barriers may not benefit from this study due to the need for informed consent and understanding of the treatment process.
Why it matters
Potential benefit: If successful, this study could provide insights into more effective and resource-efficient treatment options for patients with multiple myeloma.
How similar studies have performed: Previous studies have shown promising results with outpatient treatments for similar conditions, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Relapsed and/or refractory multiple myeloma * Treated with teclistamab, elranatamab ou talquetamab * More than 18 years old * Having received the information from the study and not having objected to participate * Day hospital care in case of clinical feasibility (good general condition, no rapid progression or major tumor burden, no current infection) and logistics (accommodated less than 30 minutes from the IUCT Oncopole for 48 hours after each dose escalation) or in conventional hospitalization at the IUCT Oncopole Exclusion Criteria: * Illiterate subjects or those with a language barrier
Where this trial is running
Toulouse
- CHU de Toulouse — Toulouse, France (Recruiting)
Study contacts
- Study coordinator: Aurore PERROT, Md, PhD
- Email: perrot.aurore@iuct-oncopole.fr
- Phone: 0531155050
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.